

## Quick reference guide

# Varenicline for smoking cessation

## 1 Guidance

- 1.1 Varenicline is recommended within its licensed indications as an option for smokers who have expressed a desire to quit smoking.
- 1.2 Varenicline should normally be prescribed only as part of a programme of behavioural support.

## 2 Implementation

NICE has developed tools to help organisations implement this guidance (listed below). These are available on our website ([www.nice.org.uk/TA123](http://www.nice.org.uk/TA123)).

- Local costing template incorporating costing report to estimate the savings and costs associated with implementation.
- Audit criteria to monitor local practice.

## Further information

### Quick reference guide

This has been distributed to healthcare professionals working in the NHS in England and Wales (see [www.nice.org.uk/TA123distributionlist](http://www.nice.org.uk/TA123distributionlist)). It is available from [www.nice.org.uk/TA123quickrefguide](http://www.nice.org.uk/TA123quickrefguide)

For printed copies, phone the NHS Response Line on 0870 1555 455 (quote reference number N1284).

## Full guidance

This contains the following sections:

- 1 Guidance
- 2 The technology
- 3 The manufacturer's submission
- 4 Consideration of the evidence
- 5 Implementation
- 6 Recommendations for further research
- 7 Related NICE guidance
- 8 Review of guidance.

The full guidance also gives details of the Appraisal Committee and the sources of evidence considered. It is available from [www.nice.org.uk/TA123guidance](http://www.nice.org.uk/TA123guidance)

## 'Understanding NICE guidance'

Information for people who want to stop smoking is available from [www.nice.org.uk/TA123publicinfo](http://www.nice.org.uk/TA123publicinfo)

For printed copies, phone the NHS Response Line on 0870 1555 455 (quote reference number N1285).

## NICE technology appraisal guidance 123

### This guidance is written in the following context

This guidance represents the view of the Institute, which was arrived at after careful consideration of the available evidence. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of healthcare professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

## Related NICE guidance

- Workplace health promotion: how to help employees to stop smoking. NICE public health intervention guidance 5 (2007). Available from: [www.nice.org.uk/PHI005](http://www.nice.org.uk/PHI005)
- Brief interventions and referral for smoking cessation in primary care and other settings. NICE public health intervention guidance 1 (2006). Available from: [www.nice.org.uk/PHI001](http://www.nice.org.uk/PHI001)
- Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. NICE technology appraisal guidance 39 (2002). Available from: [www.nice.org.uk/TA039](http://www.nice.org.uk/TA039)

NICE is developing the following guidance (details available from [www.nice.org.uk](http://www.nice.org.uk)).

- Smoking cessation services, including the use of pharmacotherapies, in primary care, pharmacies, local authorities and workplaces, with particular reference to manual working groups, pregnant women who smoke and hard to reach communities. NICE public health programme guidance (publication expected November 2007).

Published by the National Institute for Health and Clinical Excellence, July 2007; ISBN 1-84629-438-X

© National Institute for Health and Clinical Excellence, July 2007. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of the Institute.